In an effort to find a neworal cephalosporin with well-balanced antibacterial spectrum, good oral absorbability and long plasma half-life, a series of oxyimino aminothiazolyl
Since the discovery of so-called third generation oral cephalosporins, such as cefteram pivoxil1) and cefixime,2) a numberof aminothiazole cephalosporins have been developed to obtain a compound with more potent antibacterial activity, wider spectrum and better oral absorbability,3~6) for example cefpodoxime proxetil (CPDX-PR) ( Fig. 1 ) and cefdinir (CFDN) (Fig. 2) . In a previous paper, we reported the synthesis and structure-activity and structure-oral absorption relationships of 7-[(Z) Gram-negative species.8) Thus, we were prompted to investigate the antibacterial activity and the oral absorption of the "propenyl cephem" compounds (II) with insertion of vinyl moiety at the C-3 position of El101 and its analogs.
In this report, we describe the synthesis and structure-activity relationships of 3-[(£')-or (Z)-carbamoyloxypropenyl]cephems and oral absorbability of their prodrug type esters represented by the general structure (II). The comparative data of antibacterial activity and pharmacokinetics of an El 100 ester and its propenyl derivative are also discussed. Chemistry
The new cephalosporins (6, 7) with [(£")-or (Z)-substituted carbamoyloxy]propenyl at the C-3 position were prepared by the routes shownin Scheme1~3.
In Scheme 1, the 2-(2-tritylaminothiazol-4-yl)-2-acetic acids (la,9) lb) were condensed with p-methoxybenzyl 7-amino-3-chloromethyl-3-cephem-4-carboxylate (2) in DMF in the presence of dicyclohexylcarbodiimide (DCC) and 1 -hydroxybenztriazole (HOBt) to give /?-methoxybenzyl 7-[(Z)-2-(2-tritylaminothiazol-4-yl)-2-trityloxyimino or 2-(methoxyimino)acetamido] -3-chloromethyl-3 -cephem-4-carboxylate (3a, 3b). After treatment of 3a, 3b with sodium iodide, triphenylphosphine was reacted with the resultant iodomethyl cephems to afford the phosphonium salts (4a, 4b).10) The ylides which were obtained by treatment of4a or 4b with aqueous sodium hydroxide were treated with the various 2-substituted acetaldehydes (16a, 16c~16e), which were prepared according to the general method outlined in Scheme 2, to give exclusively (Z)-propenyl cephems (5a~5p).
Scheme 2 describes the general synthetic method for 2-substituted acetaldehydes (16a, 16c~16e). ter^Butyldimethylsilyloxyacetadehyde (16a)1 1} was synthesized from cz>-2-buten-l ,4-diol (14), silylated with terf-butyldimethylsilylchloride in the presence of imidazole, and treated with ozone to give aldehyde (16a). As another possible synthetic route for 5c~5d, ozonolysis of 1,4-bis(carbamoyloxy)-2-butene and l,4-bis(7V-mono substituted carbamoyl)-2-butene was tried, but this route was found to be unpromising because these butens were fragile to ozone to be decomposedduring the reaction. Af,N-Disubstituted carbamoyloxy acetaldehydes (16c~e) were able to be prepared from the same starting material (14). The hydroxy group of 14 was transformed with A^iV'-carbonyldiimidazole to activated ester (15b), which was reacted with the appropriate secondary amines to afford l ,4-bis(JV,iV-disubstituted carbamoyloxy)-2-butenes (15c~15e). Unlike carbamoyloxy or TV-monosubstituted carbamoyloxy butenes, the double bond of these butens (15c~15e) were successfully cleaved with ozone to yield aldehydes (16c~16e). Consequently, (Z)-carbamoyloxy propenyl cephems (5a~5p) were obtained by two routes, one for DEC. 1994 Scheme 1.
Abbreviation Tr=trityl PMB = 4-methoxyphenylmethyl POM= pivaloyloxymethyl unsubstituted.(5c, 5m) and mono-substituted carbamoyloxy cephems (5d~5g, 5n), and another for disubstituted carbamoyloxy cephems (5h~5j, 5p). In the former route, the ylides were coupled with the aldehyde (16a) to give terf-butyldimethylsilyloxypropenyl cephems (5a, 5k). After deprotection of the ter^-butyldimethylsilyl substituent of 5a, 5k with hydrochloric acid in aqueous acetone, the resultant (Z)-3-hydroxy-l-propenyl cephems (5b, 51) were transformed with chlorosulfonylisocyanate to afford 3-carbamoyloxy propenyl cephems (5c, 5in) or treated with alkylisocyanates in the presence of triethylamine Scheme 3. to afford 3-(mono substituted carbamoyloxy)propenyl cephems (5d~5g, 5n). In the latter route, (N,iV-disubstituted carbamoyloxy)propenyl cephems (5h~5j, 5p) were directly manufactured through the Wittig reaction of ylides with aldehydes (16c~16e). These protected cephems were treated with trifluoroacetic acid-anisole, and subsequently with formic acid to give crude materials, and purified by ODS-chromatographyto afford cephem sodium salts (6c~6p). These new cephalosporins (6c~6p) were esterified with pivaloyloxymethyl iodide to give their prodrug esters (7c~7p) in good yields.
Scheme 3 shows the synthetic route for (£)-carbamoyloxypropenyl cephem. /7-Methoxybenzyl 7-formamido-3-[(£')-3-iodol -propenyl]-cephem-4-carboxylate (8) prepared by the method reported in our previous paper10) was treated with H2O-dimethylsulfoxide in the presence of cuprous oxide and subsequently reacted with chlorosulfonylisocyanate to afford the carbamoyl cephem (10). The cleavage of 7-formamido was accomplished with concentrated hydrochloric acid to give the amino cephem (ll), which was coupled with la using DCCand HOBt to afford the protected carbamoyloxypropenyl cephem (5q).
After similar treatments to those described above in the case of 5c and 6c, (ii)-carbamoyloxypropenyl cephem (6q) and its pivaloyloxymethyl (POM)ester (7q) were prepared.
Antibacterial Activity and Oral Absorption Table 1 shows the in vitro antibacterial activity of the newcephalosporins and reference compounds, such as cefaclor (CCL), cefpod'oxime (CPDX)and CFDNagainst Gram-positive and Gram-negative bacteria. Table 2 shows the urinary recovery (%) after oral administration of POMesters (20mg/kg as the parent compound) and the relative bioavailability (%) calculated according to the following equation.
., ,.,. , Art/N (UrinaryRecovery(%)afterpodosage)^' Relative Bioavailability (BA%) =-^--x 100
(Urinary Recovery (%) after iv dosage)
Most of the new tested compoundsshowed potent activity against Gram-positive and Gram-negative bacteria including /Mactamase producing strains except for P. aeruginosa PAO1.In comparison between (Z)-carbamoyloxypropenyl cephem (6q) and its (£)-counterpart (6c), the (Z)-isomer was found to be less active against Gram-negative bacteria while it showed almost the same activity against Gram-positive bacteria. In addition, the (£)-isomer's activity was a little stronger than that of carbamoyloxymethyl As for the mono-substituted derivatives (6d~6g), modification with a more hydrophobic substituent led to reduction in potency against Gram-negative bacteria including H. influenzae, which is one of the most important pathogens in respiratory tract infection. Af,Af-Disubstituted carbamoyloxy analogues (6h~6j) showedsimilar reduction in activity against Gram-negative bacteria as well as some Gram-positive bacteria. On the contrary, the activity against H. influenzae of 7V,7V-disubstituted carbamoyloxy derivatives was found to be maintained. However, unlike the carbamoyloxymethyl type cephems (I)7), substitution at the TV-position of carbamoyloxy group did not result in increase on potency against H. influenzae.
Generally, the methoxyimino derivatives (6m1 3)~6p) were significantly less active against S. aureus and had almost the same potency against Gram-negative bacteria as hydroxyimino cephems (6c~6j). The methoxyimino derivatives exhibited a similar tendency to that of the hydroxyimino series, that is, modification with lipophilic substituents at the C-3 carbamoyloxy group led to reduction of activity against Gram-negative bacteria.
Over all, most of the hydroxyimino (Z)-carbamoyloxypropenyl cephems showed similar activity against S. aureus and stronger activity against Gram-negative species including H. influenzae than CFDN,and they exhibited stronger potency against almost all the Gram-positive and negative bacteria than CPDX, while they possessed similar activity against H. influenzae to that of CPDX.
The POMesters (7) showed moderate or good oral absorbability, as shown in Table 2 . As rather high oral absorption of (Z)-carbamoyloxy cephem (7c) was observed compared with (E)-isomer (7q), (Z)-carbamoyl propenyl cephems were synthesized and evaluated more extensively. Among them, compounds bearing more lipophilic substituents such as 7f, 7g, 7h, 7j, 7p showed good oral absorption. In particular, Af,iV-dimethylcarbamoyl derivatives (7h, 7p) showed the best absorbability. It is interesting that both 7V,7V-dimethyl derivatives exhibited the best oral absorbability in the series of (E)-carbamoyloxypropenyl cephems (II) and carbamoyloxymethyl cephems (I). However, we have not been able to obtain quantitative interpretation for this finding in spite of several physical chemistry studies. Amonga number of compounds, 7h was found to be a compoundwith well-balanced antibacterial activity and good oral absorption, so we did the pharmacokinetic studies between two types. In Fig. 4 , the plasma concentration curves after oral administration of both El 100 POM ester and its counterpart ester (7h) are depicted. Since El 100-POM showed long-lasting activity and a high Cmax in plasma compared with 7h, El 100 and its proxetil ester (El101) were chosen as candidates for further evaluation.
Experimental
XHNMRspectra were recorded on a JEOL 90Q or a Varian UNITY400 spectrometer. IR spectra were measured on a Hitachi 260-30 or a Nicolet 205 FT-IR spectrometer. Mass spectra were measured on JEOL JMS HX100. Melting points were taken on a Yamato MP21.
Determination of Antibacterial Activities All in vitro antibacterial activities are given as MIC in^g/ml required to prevent growth of bacterial culture. MICs were determined by the serial agar dilution method with incubation at 37°C for 18~20 hours with an inoculum size of about 106 cells/ml.
Oral Absorption Study
Male ICR-strain mice aged 4 weeks weighing 24~30g were used in groups of 4. The antibiotics were given to mice orally as a single dose of 20mg/kg in a suspension of 0.5% CMC.For the purpose of calculating the relative bioavailability, the parent anitbiotics were given intravenously at a single dose of 20mg/kg in solution. Urine was collected over 6 hours after dosing.
To a solution of (Z)-2-(2-tritylaminothiazol-4-yl)-2-trityloxyiminoacetic acid1) (la; 1.3 g, 1.9 mmol) in N,N-dimethylformamide (10ml), were added 1-hydroxybenztriazole (0.27g, 2mmol) and N,N*-dicyclohexylcarbodiimide (0.4g, 2mmol), and the reaction mixture was stirred for 1 hour. To the reaction mixture were added a solution of 4-methoxyphenylmethyl 7-amino-3-chloromethyl-3-cephem-4-carboxylate hydrochloride (2; 0.8 g, 2 mmol) and triethylamine (0.2 g, 2 mmol) in A^TV-dimethylformamide (4ml), and the mixture was stirred for 18 hours. After the insoluble urea was filtered off, the mixture was diluted with ethyl acetate. The organic layer was washed with water and then brine and dried over anhydrous MgSO4 and the filtrate was evaporated. The residue was chromatographed on a column of silica gel (Wako C-200, 20 g, eluent; «-hexane -ethyl acetate, 3 : 1). The fractions containing 3a were collected and evaporated under reduced pressure. The residue was solidified from diisopropyl ether to give 1.08 g of 3a (52% 
Praparation of 3b was carried out by a similar method to that described for 3a (59% 
To a solution of sodium iodide (67g, 0.45mol) in acetone (400ml) was added 3a (83g, 0.08mol), and the mixture was stirred for 1 hour. The reaction mixture was concentrated in vacuo and diluted with water (300 ml). The suspension was extracted with ethyl acetate (600 ml) and the extract was washed with 10% sodium hydrosulfite aqueous solution (200ml), water (300ml), and then brine (300ml) and dried over anhydrous MgSO4.To the filtrate was added triphenylphosphine (34g, 0.13 mol), and the mixture was stirred for 4 hours. The resulting mixture was evaporated under reduced pressure. To the residue, diisopropyl ether (2 liters) was added and the precipitate was filtered off to give HOgof 3a (97%).
Praparation of 4b was carried out by a similar method to that described for 4a (95%). 
4-Methoxyphenylmethyl
To a solution of 5a (4.99g, 4.36mmol) in acetone (50ml) was added 1 m hydrochloric acid (10ml) at room temperature, and the mixture was stirred for 2 hours. After the mixture was concentrated under reduced pressure, water (200ml) was added and the mixture was extracted with ethyl acetate (200ml). The extracted organic layer was washed with water and then brine, and dried over anhydrous MgSO4 and evaporated. The resulting solid was purified by chromatography on a column of silica gel (eluent; «-hexane-ethyl acetate, 2: 1) to yield 2.2g of5b (49 % 
To a solution of 5b (386mg, 0.375mmol) in tetrahydrofuran (15ml) at -50°C was added chlorosulfonylisocyanate (0.08 ml, 0.919 mmol) dropwise and the mixture was stirred at -20°C for 1 hour. The mixture was added to a phosphate buffer solution (pH 7, 15ml) and extracted with ethyl acetate (150 ml). The extract was washed with brine and dried over anhydrous MgSO4and evaporated. The residue was solidified from «-hexane to yield 400mgof 5c as an amorphous powder (99%). The spectral data for 5c are listed in Table 3 .
To a solution of 5b (2 g, 1.944mmol) and triethylamine (40mg, 0.4mmol) in tetrahydrofuran (40ml) was added methyl isocyanate (887mg, 15.5mmol), and the mixture was stirred at 60°C for 4 hours. After evaporation, the mixture was purified by chromatography on a column of silica gel (Wakogel C-200, 40 g, eluent; dichloromethane -acetone, 19 : 1) and triturated with rc-hexane -diisopropyl ether to yield 1 g of 5d as white powder (47%).
Preparation of 5e~5g was carried out by a method similar to that described for 5d. The spectral data for derivatives 5d~5g are listed in Table 3 .
l ,4-Bis[( l -imidazolyl)carbonyloxy] -cw-2-butene (15b)
To a solution of cw-2-buten-l,4-diol (14; 500mg, 5.7mmol) in tetrahydrofuran (10ml) at room temperature was added 7V,iV'-carbonyldiimidazole (2.3 g, 15mmol) and the mixture was stirred for 24 hours and evaporated under reduced pressure. The resulting residue was diluted with ethyl acetate and the organic layer was washed with water and then brine and dried over anhydrous MgSO4.The filtrate was evaporated under reduced pressure and the residue was crystallized from diisopropyl ether to give 1.22g of 15b as white crystals (85%). The analytical sample was recrystallized from ethyl acetate to give 15b as white crystals (70%) 1 ,4-Bis(A^,A^-dimethylcarbamoyloxy)-c/ly-2-butene (1 5c) To a solution of 15b (1 g, 3.9 mmol) in tetrahydrofuran (10 ml) was added a solution of dimethylamine (0.36g, 8mmol) in tetrahydrofuran (1.6ml), and the mixture was stirred for 5 hours. The mixture was diluted with water and extracted with ethyl acetate. The extract was washed with brine and dried over anhydrous MgSO4.The filtrate was concentrated under reduced pressure to give 0.9 g of 15c as a colorless liquid (100%). *H NMR (400MHz, CDC13) 5 2.89 (12H, s), 4.66 (4H, d, /=5Hz), 5.72 (2H, t, /=5Hz); IR (nujol)cm"1 1716; MS m/z 231 (MH+). Preparation of 15d and 15e was carried out by a method similar to that described for 15c. The spectral data for derivatives 15d, 15e are as follows. To a solution of 15c (6.33 g, 27.5mmol) in methanol (80ml) at -78°C, ozone gas was bubbled at the same temperature for 30 minutes. To the reaction mixture was added dimethylsulfide (6 ml) and the mixture was stirred at room temperature for 1 hour. After evaporation, the residue was diluted with ethyl ether. The organic layer was washed with water and then brine, and dried over anhydrous MgSO4.The filtrate was evaporated and the residue was chromatographed on a column of silica gel (Wako C-200, 120 g). The column was eluted with «-hexane-ethyl acetate (2 : 1) and the fractions containing the product were evaporated to give 4g of 16c as a colorless oil (56% Preparation of 16d and 16e was carried out by a method similar to that described for 16c. The spectral data for derivatives 16d, 16e are as follows. Preparation of 5i and 5j was carried out by a method similar to that described for 5h. The spectral data for derivatives 5h-5j are listed in Table 3 .
4-Methoxyphenylmethyl 7-[(Z)-2-(2-Tritylaminothiazol-4-yl)-2-trityloxyiminoacetamido] -3-[(Z)-3-
To a solution of 4b (10.5 g, 10.3mmol) in dichloromethane (100ml) was added 1 M aqueous sodium hydroxide solution (15 ml) and the mixture was stirred for 20 minutes. The organic layer was separated and washed with brine and dried over anhydrous MgSO4.To the resulting solution was added 16a (2.6 g, 14.8mmol), and the mixture was stirred at room temperature for 16 hours. The reaction mixture was evaporated to dryness and the residue was chromatographed on a column of silica gel (WakoC-200, 200 g). The column was eluted with «-hexane-ethyl acetate (5 : 2). The fraction containing the desired compound was collected and evaporated to give 4.30g of 5k as an amorphous powder (46%). *H NMR 
4-Methoxyphenylmethyl 7-[(
(51) Preparation of 51 was carried out by a method similar to that described for 5b (55%).
*HNMR (90MHz, CDC13) 3 3.25 and 3.70 (2H, ABq, /= 18Hz), 3.72 (3H, s), 4.00 (3H, s) 
Preparation of 5m and 5n was carried out by a method similar to that described for 5c and 5d, rsrespectively (63% and 60%). Preparation of 5p was carried out by a method similar to that described for 5h. The spectral data for 5m~5p are listed in Table 3 .
o a solution of anisole (8 ml) and trifluoroacetic acid (10ml) under ice-cooling was added 5c (1.1 g, 1.1 mmol), and the mixture was stirred at room temperature for 2 hours. After the solvent was evaporated in vacuo and the residue was triturated with diisopropyl ether (20 ml) and w-hexane (80 ml). The precipitate formed was collected by filtration and was added to a solution of 90%formic acid (10ml). After being stirred at room temperature for 3 hours, the mixture was concentrated and the residue was triturated with diisopropyl ether. The crystals were collected by filtration and mixed with sodium acetate (262 mg, 3.2 mmol) in methanol (10ml). The mixture was evaporated to dryness and the residue was crystallized with 2-propanol. The precipitate was collected by filtration to give a crude product of 6c. The solid was purified by chromatography on a column of C18 Silica Gel (YMCA-343, eluent; 5% methanol). The fractions containing the desired compoundwere concentrated under pressure and the residue was freeze-dried to give 208mg of6c (40%).
Preparation of 6d~6j, 6q, 6r was carried out by a method similar to that described for 6c. The spectral data for derivatives 6c~6j, 6q, 6r are listed in Table 4 .
To a solution of anisole (8 ml) and trifluoroacetic acid (10ml) was added 5m (0.96g, 1.1 mmol) under ice cooling, and the mixture was stirred at room temperature for 2 hours. The solvent was evaporated in vacuo and the residue was triturated with diisoprpyl ether (20ml) and «-hexane (80ml). The precipitate was collected by filtration. The crystals were mixed with sodium acetate (262mg, 3.2 mmol) in methanol (10ml). The mixture were evaporated to dryness and the residue was crystallized with 2-propanol. The precipitate was collected by filtration to give a crude product of 6m. The solid was purified by chromatography on a column of C18 Silica Gel (YMCA-343, elluent; 5% methanol). The fractions containing the desired compoundwere concentrated under pressure and the residue was freeze-dried to give 138mg of6m (24%).
Preparation of 6n~6p was carried out by a method similar to that described for 6m. The spectral data for derivatives 6m~6p are listed in Table 4 .
To a solution of 6c (137mg, 0.34mmol) in JV,7V-dimethylformamide (3ml) was added iodomethyl pivalate (83 mg, 0.34 mmol) dropwise under ice cooling and the mixture was stirred at the same temperature for 30 minutes and diluted with ethyl acetate. The reaction mixture was washed with water and then brine and dried over anhydrous MgSO4. The filtrate was concentrated in vacuo and the residue was chromatographed on a column of silica gel (Wako C-200, 20g). The column was eluted with ethyl acetate -methanol (25 : 1). The fractions containing the desired product were combined and concentrated under reduced pressure. The residue was triturated with diisopropyl ether (50ml) to yield 56mg of 7c as an amorphous powder (28%).
Preparation of 7d~7r was carried out by a method similar to that described for 7c. The spectral data for derivatives 7c~7r are listed in Table 5 . To a solution of9 (7.4g, 18.3 mmol) in tetrahydrofuran (185ml) at -50°C was added chlorosulfonyl isocyanate (3.5 ml, 40 mmol), and the mixture was stirred at the same temperature for 1 hour. The reaction mixture was added to a phosphate buffer solution (pH 7, 300ml) at 0°C and extracted with ethyl acetate. The extracts were washed with water and then brine, and dried over anhydrous MgSO4. The filtrate was concentrated under reduced pressure and the residue was chromatographed on a columnof silica gel (Wako C-200, 200g) . The fractions containing the desired compound were evaporated to give 530mg of 10 as an amorphous powder (6%).^H NMR(90MHz, DMSO-d6) S 3.75 (3H, s) (5q) To a suspension of 10 (530mg, l.lmmol) in tetrahydrofuran (15ml) and methanol (15ml) was added concentrated hydrochloric acid (0.53 ml), and the mixture was stirred for 4 hours. The mixture was diluted with ethyl acetate (200 ml) and was adjusted to pH 6 with 5% aqueous sodium carbonate solution. The organic layer was washed with water and then brine and dried over anhydrous MgSO4. The filtrate was evaporated to yield 480 mgof 4-methoxyphenymethyl 7-amino-3-[(jE>3-carbamoyloxy-l-propenyl]-
3-cephem-4-carboxylate (ll) as an amorphous powder (quantitative).
To a solution of ll (480mg, l.l mmol) in Af,7V-dimethylformamide (10ml) was added la (706mg, 1 .2mmol) and 7V,JV'-dicyclohexylcarbodiimide (244mg, 1.2mmol), 1-hydroxybenztriazole (173mg, 1.3 mmol), and the mixture was stirred for 4 hours. After the insoluble urea was filtered off, the mixture was diluted with ethyl acetate. The organic layer was washed with water and then brine and dried over anhydrousMgSO4 and the the filtrate was evaporated. The residue was chromatographedon a column of silica gel (Wako C-200, 20g, eluent; dichloromethane-ethyl acetate, 9 : 1). The fractions containing the desired product were collected and evaporated under reduced pressure to give 620mgof 5q as an amorphous powder (53%).
The spectral data for 5q are listed in Table 3 .
